Migren dan Permasalahannya: Pendekatan Terapi Akut dan Preventif

Restu Susanti

Abstract


Abstrak

 Migren merupakan salah satu jenis nyeri kepala primer yang banyak dikeluhkan. Migren yang tidak ditangani dengan baik akan menjadi kronis dan menimbulkan disabilitas yang akan mempengaruhi kualitas hidup penderitanya selain pembiayaan yang besar. Mengenali pencetus, tata laksana akut yang tepat dan pemberian terapi preventif harus dilakukan. Terapi preventif bertujuan untuk mengurangi frekuensi, severitas, durasi serangan, meningkatkan respon terapi akut sehingga akan meningkatkan kualitas hidup dan mengurangi disabilitas. Terapi preventif dikatakan berhasil bila frekuensi serangan berkurang 50% setiap bulannya selama tiga bulan.

 Kata kunci — Luaran, migren, terapi preventif

 

Abstract

 Migraine is one of primary headache which is often complained by patients. Migraines that are not treated properly will become chronic and cause disabilities that will affect the quality of life of sufferers in addition to large financial expenditure. Physicians have to be able to recognize the triggers, performe appropriate acute management, and give preventive therapy must be carried out. Preventive therapy aims to reduce the frequency, severity, duration of attacks, increase the response of acute therapy so that it will improve quality of life and reduce disability. The succesful preventive therapy is successful if the frequency of attacks is reduced by 50% every month for three months.

Keywords — Migraine, outcomes, preventive therapy


Keywords


Migraine; outcomes; preventive therapy

Full Text:

PDF

References


. Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211.

. American Headache Society. The American Headache Society Position Statement On Integrating New Migren Treatment Into Clinical Practice.Headache.2019;59:1-18

. Silberstein SD. Preventive Migren Treatment. Continuum (Minneap Minn). 2015;21(4): 973-89

. Muñoz-Cerón J, Rueda Sánchez M, Pradilla-Vesga O, Volcy M, Hernández N, Ramírez S et al. Guideline on the preventive treatment of chronic migraine, chronic tension type headache, hemicrania continua and new daily persistent headache on behalf of the Colombian Association of Neurology. Acta Neurol Colomb. 2019;35(3):140-56.

. Diener HC, Lee DH, Nagel S, Dresler T, Gaul C, Kuhn KH, dkk. Treatment of Migren attacks and prevention of migrene: Guidelines by the German Migraine dan Headache Society and German Society of Neurology. Clin Transl Neurosci.2019:1-40

. King CT, Gegg CV, Yu Hu SN, Lu HS, Chan BM, Berry KA. Discovery of the Migrene Prevention Theurapetic Aimovig (Erenumab), the First FDA-Approved Antibody Against G-Protein Coupled Receptor. ACS Pharmacol. Transl. Sci. 2019;2:485-90

. Silberstein SD, Winner PK, Chmiel JJ. Migrene preventive medication reduces resource utilization. Headache. 2003;43(3): 171-8

. Kelompok Studi Nyeri Kepala, PERDOSSI. Konsensus Nasional V. Diagnostik dan Penatalaksanaan Nyeri Kepala. 2018. Hal 13-37

. Estemalik E and Tepper S. Preventive treatment in migrene and the new US guidelines. Neuropsychiatr Dis Treat 2013;9:709-20

. Global Burden of Disease 2016 Headache Collaborator Group. Global, regional, and national burden of migrene and tension-type headache, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol 2018; 17: 954–76.

. Diamond S, Bigal ME, Silberstein S, Loder E, Reed M, Lipton RB. Patterns of diagnosis and acute and preventive treatment for migraine in the United States: results from the American Migraine Prevalence and Prevention study [published correction appears in Headache. 2007 Oct;47(9):1365]. Headache. 2007;47(3):355‐63.

. States: results from the American Migrene Prevalence and Prevention study. Headache 2007;47:355.

. Matthew NT. Pathophysiology of Chronic Migrene dan Mode of Action of Preventive Medication. Headache.2011;

. Goadsby, PJ, Holland PR. Patophysiology of Migrene :An Update. Neurologic Clinics. 2019; 37(4), 651–71.doi:10.1016/j.ncl.2019.07.008

. Marmura, MJ. Triggers, Protectors, and Predictors in Episodic Migrene. Curr Pain Headache Rep.2018;22:81

. Hoffmann J and Recober A. Migren and Triggers: Post hoc ergo propter hoc?.Curr Pain Headache Rep.2013;17(10): 1-11

. The Migren Trust. Common Triggers. https://www.migrenetrust.org/about-migrene/trigger-factors/common-triggers/ (Last accessed Februari 2020)

. Antonaci F, Ghiotto N, Wu S, Pucci E, Costa A. Recent advances in migrene therapy. Springerplus. 2016;5:637. Published 2016 May 17. doi:10.1186/s40064-016-2211-8

. Scottish Intercollegiate Guidelines Network-Healthcare Improvement Scotland. Pharmacological management of migrene. Edinburgh: SIGN; 2018. SIGN publication no.155. February 2018:15. Available from URL: http://www.sign.ac.uk

. Bird S, Derry S, Moore RA. Zolmitriptan for acute migrene attacks in adults. Cochrane Database Syst Rev. 2014;5:CD008616.

. Puledda F, Messina R, Goadsby PJ. An update on migrene: current understanding and future directions. J Neurol. 2017;264: 2031-9

. Puledda F and Shields K. Non-Pharmacological Approaches for Migrene. Neurotherapeutics. 2018; 15:336-45




DOI: https://doi.org/10.33854/heme.v4i1.903

DOI (PDF): https://doi.org/10.33854/heme.v4i1.903.g336

Refbacks

  • There are currently no refbacks.


Creative Commons License   Health and Medical Journal This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.